Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide in Amyotrophic Lateral Sclerosis
NCT07834450Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Oct 2026
- Primary completion
- Oct 2028
01
Overview
Phase 2, randomised, open-label trial of cyclophosphamide in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Huashan Hospital. Primary endpoint: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised at 48 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
cyclophosphamide
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07834450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07834450.